MARKET

BCRX

BCRX

BioCryst Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.45
+0.10
+1.87%
After Hours: 5.46 +0.01 +0.18% 19:53 05/22 EDT
OPEN
5.30
PREV CLOSE
5.35
HIGH
5.47
LOW
5.23
VOLUME
3.63M
TURNOVER
--
52 WEEK HIGH
6.29
52 WEEK LOW
1.380
MARKET CAP
840.35M
P/E (TTM)
-5.7654
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average BCRX stock price target is 8.00 with a high estimate of 13.00 and a low estimate of 4.000.

EPS

BCRX News

More
Edited Transcript of BCRX earnings conference call or presentation 6-May-20 12:30pm GMT
Thomson Reuters StreetEvents · 1d ago
Apellis on go to file U.S. application for pegcetacoplan for rare blood disorder
On the heels of its meeting with the FDA, Apellis Pharmaceuticals (NASDAQ:APLS) announced that it expects to file a marketing application in H2 seeking app
seekingalpha · 4d ago
Moving Average Crossover Alert: BioCryst Pharmaceuticals
Zacks · 05/18 14:30
Is the Options Market Predicting a Spike in BioCryst Pharmaceuticals (BCRX) Stock?
Zacks · 05/18 14:21
BioCryst's Shares March Higher, Can It Continue?
Zacks · 05/15 12:53
BioCryst Celebrates HAE Patients with HAE Global Walk
GlobeNewswire · 05/15 12:00
BioCryst: What Past Data Says About Galidesivir In SARS-CoV-2
Seeking Alpha - Article · 05/14 19:57
Is BioCryst Pharmaceuticals (BCRX) Stock Outpacing Its Medical Peers This Year?
Is (BCRX) Outperforming Other Medical Stocks This Year?
Zacks · 05/13 15:30

Industry

Biotechnology & Medical Research
+1.01%
Pharmaceuticals & Medical Research
+0.05%

Hot Stocks

Symbol
Price
%Change

About BCRX

BioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company's drug candidates include RAPIVAB, RAPIACTA, ALPIVAB, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, Galidesivir and Forodesine. Its product RAPIVAB contains peramivir. ALPIVAB is an intravenous neuraminidase inhibitor. Galidesivir is a broad-spectrum antiviral (BSAV) research program developed for the treatment of hemorrhagic fever viruses. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor in development by Mundipharma as a treatment for cancer.
More

Webull offers kinds of BioCryst Pharmaceuticals, Inc. stock information, including NASDAQ:BCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCRX stock news, and many more online research tools to help you make informed decisions.